CatalystMarker
Sign in
← board

AZN

AstraZenecadistress 3/10 · well-funded / low risk
$167.33-1%today-20% from 52w high
astrazeneca.com96,100 employeesFounded 1992Cambridge, United KingdomDrug Manufacturers - General
Oncology 4Cardiovascular 1Immunology / Inflammation 1Metabolic / Obesity 1
Lead: Non-small Cell Lung Cancer · est. market ~$35B (approx, global)
Revenue
$15288M
Liquidity
$7675M
Runway
—
Shares 1y
—

Price & events

-7.8% over 6M
$165$187$209Jan 26Apr 26Jul 266.6Mdilution: 424B2 offering (2026-02-27)dilution: FWP offering (2026-02-26)dilution: 424B2 offering (2026-02-25)
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-1.2%
1W
-7.6%
1M
-13.0%
3M
-9.1%
6M
+16.6%
1Y
+9.7%
2Y
+59.6%
5Y
+87.5%
All

Overview

Volume
249.08K
52 Week Range
$137 – $209
Float Shares
1.54B
Short %
0.10%
% Held by Insiders
0.05%
% Held by Institutions
68.36%
RVOL
0.11x
Beta
0.23

Pipeline stages · 45 programs

AZD0486, R-mini-CHOP
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-06-19
Elecoglipron
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-07-05
Durvalumab, Oleclumab, Monalizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-07-12
Ravulizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-07-12
AZD9592, Osimertinib, 5-Fluorouracil (5-FU)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-08-03
AZD8965 low dose, AZD8965 medium dose, AZD8965 high dose
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-09-14
Anifrolumab, APFS
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-10-05
AZD2962
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-10-20
Acalabrutinib, Venetoclax
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-10-31
ICS-LABA, benralizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-11-03
Show all 45 programs · 35 more ▾
volrustomig
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-11-16
AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-11-17
Datopotamab deruxtecan (Dato-DXd), Docetaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-11-20
AZD3470, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-12-04
Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-12-29
Rilvegostomig, Pembrolizumab, Carboplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-01-02
AZD0516, AZD9574
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-01-18
Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-01-19
AZD9750, AZD5305
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-01-26
Eplontersen, ALXN2220
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-02-06
AZD2265 (FPI-2265), AZD9574, Docetaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-02-13
AZD3632, Posaconazole
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-02-15
Tezepelumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-03-13
Tremelimumab, Rilvegostomig, Bevacizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-03-16
AZD6621
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-03-29
Saruparib, Abiraterone, Prednisolone/Prednisone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-03-30
AZD2287, AZD2275, AZD2284
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-04-16
AZD0120
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-05-01
GP MDI, BFF MDI
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-05-23
Osimertinib 80 mg/40 mg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-05-30
Autologous, engineered T Cells targeting TP53 R175H
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-07-31
Sonesitatug vedotin, Rilvegostomig, Nivolumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-08-16
AZD6750, rilvegostomig
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-10-02
AZD0780
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-10-26
AZD4045, Daratumumab, Aldesleukin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-10-30
Baxdrostat/dapagliflozin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-12-17
Benralizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-12-28
Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-12-28
Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level, Sodium Zirconium Cyclosilicate (S
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-02-21
Camizestrant, Tamoxifen, Anastrozole
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-03-04
AZD4956, Saruparib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-03-29
Balcinrenone/dapagliflozin, Dapagliflozin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-07-01
AZD5305, Enzalutamide, Abiraterone Acetate
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-04-11
Surovatamig, R-CHOP, R-CVP
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-08-29
ALXN2350
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2032-01-27

Pipeline · 80 trials · 80 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2028-06-19
Estimated 50%
readout ~2028-07-19
Phase 1AZD0486 IVB-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma—active not recruiting
2028-07-05
Estimated 50%
readout ~2028-09-18
Phase 3Elecoglipron, DapagliflozinType 2 Diabetes Mellitus—not yet recruiting
2028-07-12
Estimated 50%
readout ~2028-09-25
Phase 3Durvalumab, DomvanalimabNon-Small Cell Lung Cancer—recruiting
2028-07-12
Estimated 50%
readout ~2028-09-25
Phase 3RavulizumabIgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis, Henoch-schonlein Purpura Nephritis, IgA Vasculitis—recruiting
2028-07-13
Estimated 50%
readout ~2028-09-26
Phase 3ElecoglipronType 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease—not yet recruiting
Show all 80 trials · 75 more ▾
ReadoutPhaseDrugIndicationEnrollStatus
2028-07-14
Estimated 50%
readout ~2028-09-27
Phase 3Elecoglipron, DapagliflozinType 2 Diabetes Mellitus—not yet recruiting
2028-07-31
Estimated 50%
readout ~2028-10-14
Phase 3ElecoglipronWeight Management—not yet recruiting
2028-08-03
Estimated 50%
readout ~2028-09-02
Phase 1AZD9592, Osimertinib, 5-Fluorouracil (5-FU)Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms—active not recruiting
2028-09-14
Estimated 50%
readout ~2028-10-29
Phase 2AZD8965 low dose, AZD8965 medium dose, AZD8965 high doseIdiopathic Pulmonary Fibrosis (IPF)—recruiting
2028-10-05
Estimated 50%
readout ~2028-12-19
Phase 3AnifrolumabSystemic Lupus Erythematosus—recruiting
2028-10-20
Estimated 50%
readout ~2028-11-19
Phase 1AZD2962Haematologic Neoplasms—recruiting
2028-10-31
Estimated 50%
readout ~2029-01-14
Phase 3Durvalumab, (Osimertinib cohort, single-armCarcinoma, Non-Small-Cell Lung—active not recruiting
2028-10-31
Estimated 50%
readout ~2029-01-14
Phase 3Durvalumab, Methotrexate, VinblastineUrinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine—recruiting
2028-10-31
Estimated 50%
readout ~2029-01-14
Phase 3RavulizumabNMOSD, Neuromyelitis Optica Spectrum Disorder—not yet recruiting
2028-10-31
Estimated 50%
readout ~2028-12-15
Phase 2Acalabrutinib, Venetoclax, RituximabMantle Cell Lymphoma (MCL)—active not recruiting
2028-11-03
Estimated 50%
readout ~2029-01-17
Phase 3ICS-LABA, benralizumabEosinophilic Asthma—recruiting
2028-11-16
Estimated 50%
readout ~2029-01-30
Phase 3Volrustomig, Pemetrexed, CarboplatinUnresectable Pleural Mesothelioma—active not recruiting
2028-11-17
Estimated 50%
readout ~2029-01-31
Phase 3AZD5335, Mirvetuximab Soravtansine (MIRV), PaclitaxelEpithelial Ovarian Cancer—recruiting
2028-11-20
Estimated 50%
readout ~2029-02-03
Phase 3Dato-DXd, Durvalumab, PembrolizumabBreast Cancer—active not recruiting
2028-11-30
Estimated 50%
readout ~2029-02-13
Phase 3Durvalumab, Chemotherapy phase, Olaparib phaseAdvanced or Recurrent Endometrial Cancer—active not recruiting
2028-11-30
Estimated 50%
readout ~2029-01-14
Phase 2Volrustomig, Cisplatin, CarboplatinSub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)—recruiting
2028-12-04
Estimated 50%
readout ~2029-01-18
Phase 1/2AZD3470, Datopotamab deruxtecanAdvanced Solid Tumors That Are MTAP Deficient—recruiting
2028-12-29
Estimated 50%
readout ~2029-03-14
Phase 3Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2Chronic Obstructive Pulmonary Disease, COPD—recruiting
2029-01-02
Estimated 50%
readout ~2029-03-18
Phase 3Rilvegostomig, Capecitabine, Gemcitabine/CisplatinBiliary Tract Cancer—active not recruiting
2029-01-18
Estimated 50%
readout ~2029-03-04
Phase 1/2AZD0516, AZD9574Metastatic Prostate Cancer—recruiting
2029-01-19
Estimated 50%
readout ~2029-04-04
Phase 3Trastuzumab deruxtecan, Rilvegostomig, PembrolizumabEndometrial Cancer—recruiting
2029-01-26
Estimated 50%
readout ~2029-03-12
Phase 1/2AZD9750, AZD5305Prostate Cancer—recruiting
2029-01-26
Estimated 50%
readout ~2029-04-11
Phase 3AnifrolumabSystemic Lupus Erythematosus—recruiting
2029-01-29
Estimated 50%
readout ~2029-04-14
Phase 3Datopotamab deruxtecan (Dato-DXd), DocetaxelNon-small Cell Lung Cancer (NSCLC)—recruiting
2029-02-05
Estimated 50%
readout ~2029-04-21
Phase 3Rilvegostomig, Pembrolizumab, CarboplatinNon-small Cell Lung Cancer—recruiting
2029-02-06
Estimated 50%
readout ~2029-03-23
Phase 2Eplontersen, ALXN2220Transthyretin Amyloid Cardiomyopathy (ATTR-CM)—recruiting
2029-02-13
Estimated 50%
readout ~2029-04-29
Phase 3AZD2265, Cabazitaxel, AbirateroneMetastatic Castration-resistant Prostate Cancer—recruiting
2029-02-15
Estimated 50%
readout ~2029-04-01
Phase 1/2AZD3632, PosaconazoleAcute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes—recruiting
2029-02-23
Estimated 50%
readout ~2029-04-09
Phase 1/2Rilvegostomig, Cisplatin, CarboplatinAdvanced or Metastatic Non-small Cell Lung Cancer—recruiting
2029-03-13
Estimated 50%
readout ~2029-05-27
Phase 3TezepelumabChronic Obstructive Pulmonary Disease (COPD)—recruiting
2029-03-13
Estimated 50%
readout ~2029-05-27
Phase 3TezepelumabChronic Obstructive Pulmonary Disease (COPD)—recruiting
2029-03-16
Estimated 50%
readout ~2029-05-30
Phase 3Tremelimumab, Rilvegostomig, BevacizumabHepatocellular Carcinoma—recruiting
2029-03-29
Estimated 50%
readout ~2029-05-13
Phase 1/2AZD6621Prostate Cancer—recruiting
2029-03-30
Estimated 50%
readout ~2029-06-13
Phase 3Saruparib (AZD5305), Camizestrant, AbemaciclibAdvanced Breast Cancer—recruiting
2029-04-06
Estimated 50%
readout ~2029-05-21
Phase 2Rilvegostomig, Ramucirumab, Dato-DXdNon-Small Cell Lung Cancer—recruiting
2029-04-16
Estimated 50%
readout ~2029-05-16
Phase 1AZD2287, AZD2275, AZD2284Metastatic Castration-Resistant Prostate Cancer—recruiting
2029-04-22
Estimated 50%
readout ~2029-06-06
Phase 2Acalabrutinib, RituximabDiffuse Large B-Cell Lymphoma—recruiting
2029-04-27
Estimated 50%
readout ~2029-07-11
Phase 3Rilvegostomig, Trastuzumab deruxtecan, TrastuzumabHER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma—recruiting
2029-05-01
Estimated 50%
readout ~2029-06-15
Phase 1/2AZD0120, Cyclophosphamide, FludarabineLupus Erythematosus, Systemic—recruiting
2029-05-01
Estimated 50%
readout ~2029-06-15
Phase 2Acalabrutinib, VenetoclaxChronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)—recruiting
2029-05-03
Estimated 50%
readout ~2029-06-17
Phase 1/2AZD3470, PembrolizumabLymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), PTCL-NOS, ALCL, AITL—recruiting
2029-05-23
Estimated 50%
readout ~2029-07-07
Phase 2GP MDI, BFF MDIAsthma—recruiting
2029-05-30
Estimated 50%
readout ~2029-07-14
Phase 2OsimertinibLung Cancer—recruiting
2029-06-30
Estimated 50%
readout ~2029-09-13
Phase 3DurvalumabSmall Cell Lung Carcinoma—recruiting
2029-06-30
Estimated 50%
readout ~2029-08-14
Phase 2OsimertinibNon-small Cell Lung Cancer—active not recruiting
2029-07-31
Estimated 50%
readout ~2029-10-14
Phase 3Rilvegostomig, Durvalumab, Gemcitabine/CisplatinBiliary Tract Cancer—recruiting
2029-07-31
Estimated 50%
readout ~2029-08-30
Phase 1Autologous, engineered T Cells targeting TP53 R175HNon-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer—recruiting
2029-08-15
Estimated 50%
readout ~2029-09-29
Phase 1/2AZD0120Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis—recruiting
2029-08-16
Estimated 50%
readout ~2029-10-30
Phase 3Sonesitatug vedotin, Rilvegostomig, NivolumabGastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer—recruiting
2029-09-25
Estimated 50%
readout ~2029-11-09
Phase 1/2AZD2265 (FPI-2265), AZD9574, DocetaxelMetastatic Prostate Cancer—recruiting
2029-10-02
Estimated 50%
readout ~2029-11-16
Phase 1/2AZD6750, rilvegostomigMelanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma—recruiting
2029-10-26
Estimated 50%
readout ~2030-01-09
Phase 3AZD0780Cardiovascular Disease—recruiting
2029-10-30
Estimated 50%
readout ~2029-12-14
Phase 1/2AZD4045, Daratumumab, AldesleukinRelapsed or Refractory Multiple Myeloma—not yet recruiting
2029-11-22
Estimated 50%
readout ~2030-01-06
Phase 2Osimertinib 80 mg/40 mgStage II-IIIB Non-small Cell Lung Carcinoma—active not recruiting
2029-12-17
Estimated 50%
readout ~2030-03-02
Phase 3Baxdrostat and dapagliflozinHeart Failure—recruiting
2029-12-18
Estimated 50%
readout ~2030-03-03
Phase 3Baxdrostat/dapagliflozinChronic Kidney Disease and Hypertension—recruiting
2029-12-28
Estimated 50%
readout ~2030-03-13
Phase 3Datopotamab Deruxtecan, Rilvegostomig, PembrolizumabNon-Small Cell Lung Cancer—recruiting
2029-12-28
Estimated 50%
readout ~2030-03-13
Phase 3BenralizumabAsthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)—not yet recruiting
2030-01-17
Estimated 50%
readout ~2030-04-02
Phase 3Rilvegostomig, PembrolizumabCarcinoma, Non-Small Cell Lung—recruiting
2030-02-21
Estimated 50%
readout ~2030-05-07
Phase 3Volrustomig, Casdatifan, NivolumabAdvanced Clear Cell Renal Cell Carcinoma—active not recruiting
2030-02-21
Estimated 50%
readout ~2030-05-07
Phase 3Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level, Sodium Zirconium Cyclosilicate (SHyperkalaemia—recruiting
2030-03-04
Estimated 50%
readout ~2030-05-18
Phase 3Camizestrant, Tamoxifen, AnastrozoleBreast Cancer, Early Breast Cancer—recruiting
2030-03-29
Estimated 50%
readout ~2030-05-13
Phase 1/2AZD4956, SaruparibSolid Tumours—recruiting
2030-04-17
Estimated 50%
readout ~2030-07-01
Phase 3volrustomigLocally Advanced Head and Neck Squamous Cell Carcinoma—recruiting
2030-05-05
Estimated 50%
readout ~2030-07-19
Phase 3BenralizumabAsthma—recruiting
2030-05-28
Estimated 50%
readout ~2030-07-12
Phase 2Durvalumab, Oleclumab, MonalizumabNon-small Cell Lung Cancer—recruiting
2030-06-10
Estimated 50%
readout ~2030-08-24
Phase 3AZD0486, R-mini-CHOPLarge B-cell Lymphoma—recruiting
2030-07-01
Estimated 50%
readout ~2030-09-14
Phase 3Balcinrenone/dapagliflozin, DapagliflozinRenal Insufficiency, Chronic—not yet recruiting
2030-09-03
Estimated 50%
readout ~2030-10-18
Phase 2Anifrolumab, APFSSystemic Lupus Erythematosus—not yet recruiting
2030-11-18
Estimated 50%
readout ~2031-02-01
Phase 3Rilvegostomig, Pembrolizumab, CarboplatinNon-squamous Non-small Cell Lung Cancer—recruiting
2031-04-11
Estimated 50%
readout ~2031-05-26
Phase 1/2AZD5305, Enzalutamide, Abiraterone AcetateMetastatic Prostate Cancer—active not recruiting
2031-08-29
Estimated 50%
readout ~2031-11-12
Phase 3SurovatamigChronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV—recruiting
2031-11-26
Estimated 50%
readout ~2032-02-09
Phase 3Surovatamig, R-CHOP, R-CVPUntreated Follicular Lymphoma—recruiting
2032-01-27
Estimated 50%
readout ~2032-03-12
Phase 1/2ALXN2350BAG3 Mutation Associated Dilated Cardiomyopathy—recruiting
2033-03-31
Estimated 50%
readout ~2033-06-14
Phase 3Saruparib, Abiraterone, Prednisolone/PrednisoneProstate Cancer—recruiting

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (14)

  • KOSELUGOSELUMETINIB2025 · Prescription
  • TRUQAPCAPIVASERTIB2023 · Prescription
  • SYMBICORT AEROSPHEREBUDESONIDE2023 · Prescription
  • AIRSUPRAALBUTEROL SULFATE2023 · Prescription
  • CALQUENCEACALABRUTINIB MALEATE2022 · Prescription
  • KOSELUGOSELUMETINIB SULFATE2020 · Prescription
  • LOKELMASODIUM ZIRCONIUM CYCLOSILICATE2018 · Prescription
  • CALQUENCEACALABRUTINIB2017 · Prescription
  • LYNPARZAOLAPARIB2017 · Prescription
  • BEVESPI AEROSPHEREFORMOTEROL FUMARATE2016 · Prescription

Capital structure — dilution & financing

Shares out: — · 3 offerings/1y · 0 PIPEs
  • 2026-02-27424B2offering
  • 2026-02-26FWPoffering
  • 2026-02-25424B2offering
  • 2025-02-05EFFECTshelf_effective
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $214 (+28% upside) · 10 analysts
  • 2025-02-13UBSNeutral → Buy
  • 2024-11-20UBSSell → Neutral
  • 2024-09-11Erste GroupHold → Buy
  • 2024-08-12TD CowenBuy

Competitors — Non-small Cell Lung Cancer

  • ABBVAbbVie Inc.$451.1B · D2
  • MRKMerck & Co., Inc.$318.8B · D3
  • NVSEFNOVARTIS AG$292.0B · D3
  • PFEPFIZER INC$142.2B · D3
  • REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
  • RVMDRevolution Medicines, Inc.$40.3B · D1
  • IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
  • CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
  • MAIAMAIA Biotechnology, Inc.$78M · D5

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.